On Tuesday, Mumbai-based pharmaceutical multinational Cipla received Drugs Controller General of India (DCGI) nod to import Moderna's Covid-19 vaccine for restricted emergency use in India.
- Moderna had earlier sought regulatory approval for its Covid-19 vaccine in India.
Moderna has further informed that the United States government has agreed to donate a certain number of its vaccine doses through the global initiative of COVAX to India and has sought approval from the Central Drugs Standard Control Organisation (CDSCO) for the same.
- On behalf of the US vaccine maker, Mumbai based Cipla has applied for the import and marketing authorisation of the jabs.
Moderna's method to protect against Covid-19 relies on messenger RNA (mRNA) to program cells to generate immunity to the coronavirus. The vaccine has shown more than 90 per cent efficacy in clinical trials in protecting against COVID-19.
0 Comments